Science Group PLC Form 8 (OPD) - Science Group plc (9055B)
26 September 2018 - 4:00PM
UK Regulatory
TIDMSAG
RNS Number : 9055B
Science Group PLC
26 September 2018
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Science Group plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): N/A
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Science Group plc
Use a separate form for each offeror/offeree
------------------
(d) Is the discloser the offeror or the offeree? OFFEREE
------------------
(e) Date position held: 25 September 2018
The latest practicable date prior to the disclosure
------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect NO
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
------------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security: Ordinary shares of 1 pence each
Interests Short positions
------------------- ------------------
Number % Number %
----------- ------ ----------- -----
(1) Relevant securities owned and/or controlled: N/A N/A N/A N/A
----------- ------ ----------- -----
(2) Cash-settled derivatives: N/A N/A N/A N/A
----------- ------ ----------- -----
(3) Stock-settled derivatives (including options) and agreements to N/A N/A N/A N/A
purchase/sell:
----------- ------ ----------- -----
N/A N/A N/A N/A
TOTAL:
----------- ------ ----------- -----
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: N/A
Details, including nature of the rights concerned and relevant percentages: N/A
----
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the party to the offer making
the disclosure:
(a) Ordinary Shares of 1 pence each held by directors of Science Group plc
Science Group % of Science Group
Director Ordinary Shares issued share capital
------------------ ----------------- ----------------------
Martin Ratcliffe 13,412,906 33.51%
David Courtley 375,000 0.94%
Rebecca Archer 60,000 0.15%
------------------ ----------------- ----------------------
(b) Science Group plc 2013 Performance Share Plan granted to directors of Science Group plc
Maximum number
of ordinary Date of Exercise Exercise
Director shares awarded grant price period
--------------- ---------------- ------------ ---------- ------------
Rebecca Archer 25,000 3 Sep 2015 1.0 pence 3 Sep 2018
to 3 Sep
2025
Rebecca Archer 25,000 12 Aug 2016 1.0 pence 12 Aug 2019
to 12 Aug
2026
Rebecca Archer 25,000 6 Sep 2017 1.0 pence 6 Sep 2020
to 6 Sep
2027
Rebecca Archer 100,000 14 May 2018 1.0 pence 14 May 2023
to 14 May
2028
--------------- ---------------- ------------ ---------- ------------
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer making the disclosure or any person acting
in concert with it:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert with it, and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
---
Date of disclosure: 26 September 2018
Contact name: Sarah Cole,
Group Legal Counsel & Company Secretary
-----------------------------------------
Telephone number: 01223 875200
-----------------------------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's disclosure requirements on
+44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FEEEALNSALFPEFF
(END) Dow Jones Newswires
September 26, 2018 02:00 ET (06:00 GMT)
Science (LSE:SAG)
Historical Stock Chart
From Apr 2024 to May 2024
Science (LSE:SAG)
Historical Stock Chart
From May 2023 to May 2024